A Bioprinter is a device that can manufacture 3D parts with a customized external structure and a meshed internal structure from different biomaterials, seeded with cells. This can help to produce in vitro 3D constructs for tissue regeneration and drug development and to scale up the process towards the clinical application.
A unique and innovative ready-to-use 3D-enriched Cancer Stem Cell solution for drug compound screening. - Enhances the biological relevance of your pre-clinical invitro CSC 3D-based culture efficacy assays for novel cancer treatment discovery and validation. - Helps you accelerate the discovery of novel cancer treatments that put an end to relapse and metastasis.
Versatile platform that can be applied to a large variety of proteins. It consists on the iteration of cycles consisting on in silico and in vitro techniques. Thanks to IPROTech and the human expertise of the Iproteos Team, we are able to quickly and efficiently discover new peptidomimetic drugs for several targets.
Identification of biomarkers based on genomic experiments
Making offers to identify biomarkers associated with the diagnostic and risk for a specific disease or drug response through of differential gene expression, methylation analysis or association of polymorphisms.For this purpose we offer experimenal design, biological (massive analysis and posterior validation) and bioinformatic analysis.
Zebrafish toxicology and efficacy assays for preclinical testing.
BIOBIDE is a Biotech whose aim is to accelerate R&D process minimizing risks through zebrafish animal model, thanks to automated and innovative tools, adding value to clients R&D&i.
Biobide has developed and validated several fast and cost-effective Toxicity & Efficacy Assays and is the unique specialist in zebrafish Technologies and Services working under a GLP environment providing prompt, clear and relevant information to develop chemicals.
Biobide is specialized developing tailor made solutions based on Customer´s requirements, such as disease models generation, target validation as well as customization of validated assays:
Breeding and Biomedical Research Centre focused on the pig model
Complete CRO services, GLP certified, with our own bred miniature pigs, addressed to obtain valuable product efficacy, toxicology, pharmacokinetics or proof of concept information for pharmaceuticals. And also run in-vivo trials with Medical devices during the development process to improve product knowledge, minimize risk, convince the market and attract investment.
Glecex offers in vitro assays in cell-free systems for screening of biological activities. The in vitro assays are useful as screening tools for the development and optimization of new natural extracts, ingredients, functional foods, cosmetics, etc.
The assays are developed and validated by our scientific team, so that we can adapt to different matrices.
Monitorización de drogas terapéuticas (MDT) y ensayos de toxicidad: evaluación de la eficacia y seguridad de compuestos en fase pre-clínica.
Medición de signos vitales: Peso corporal, temperatura corporal e índice organosomático (IOS).
Medición de creatinina en suero y análisis de nitrógeno ureico en la sangre (BUN).
Medición de creatinina en orina.
Cálculo de la eliminación de creatinina.
Farmacocinética compartimental: Administración (entera y Parenteral), absorción (medición de la fracción y la velocidad a la cual la dosis administrada de un fármaco alcanza su diana terapéutica), distribución (medición de la concentración del fármaco en fluídos biológicos y órganos a distintos tiempos después de su administración) y metabolismo y excreción (constante de eliminación y eliminación).
Cálculo del Nivel del Efecto Biológico Mínimo Anticipado (MABEL): determinación de la concentración de uso seguro y con efecto terapéutico deseado del fármaco para el establecimiento de un óptimo tratamiento en el paciente.
Cancer stem cells show the unique ability to grow as floating spheroids when seeded in suspension with defined culture media. Tumor spheroid 3D cell culture systems allow stronger, more efficient an reliable drug screening than conventional 2D based monolayer culture systems currently in use. From compound validation to 96 well based HTS. This assay is optimized for breast, colon, lung, prostate, pancreas and glioblastoma cell lines, although can accomodate others. We carry on a toxicity pre-screening to discard non-specific cytotoxics, aiming to uncover molecules targeting the cancer stem cell compartment.